Researcher List - Sidebar Search Title


Quick Search

ri-custom-search Portlet

Asset Publisher

angle-left Marc Rodger, MD, M.Sc.

Senior Scientist, RI-MUHC , 5252 de Maisonneuve

Cardiovascular Health Across the Lifespan Program

Centre for Outcomes Research and Evaluation



Venous thrombosis • pulmonary embolism • pregnancy • anticoagulation • diagnosis • clinical decision rules • networks

Research Focus

My research focuses on venous thrombosis. I lead multinational randomised trials and cohort studies that seek to change clinical practice in venous thrombosis. This work has been awarded over $38 million in peer-reviewed funding (over $22 million obtained as principal investigator). My team has confirmed a weak link between thrombophilia and placental mediated pregnancy complications. We have conducted trials that showed that blood thinners do not prevent these complications, changing a common practice and sparing many women the need to inject blood thinners daily throughout pregnancy. I derived and validated a tool, “Men continue and HERDOO2,” that is used worldwide to assist in deciding whether to anticoagulate venous thrombosis lifelong, and my team is currently exploring whether an inexpensive and generic cholesterol-lowering drug might reduce the risk of venous thrombosis. I co-founded and co-direct the CIHR-funded CanVECTOR (Canadian Venous Thrombosis Clinical Trials and Outcomes Research) Network ( and founded the International Network of Venous Thrombosis Clinical Research Networks (INVENT;

Selected Publications

Click on Pubmed to see my current publications list

  • Rodger MA, Le Gal G, Anderson DR, et al and for the REVERSE II Study Investigators* Validating the HERDOO2 Rule to Guide Treatment Duration for Women with Unprovoked Venous Thrombosis: A Multi-National Prospective Cohort Management Study. BMJ 2017;365:j1065.

  • Rodger MA, Gris J-C, de Vries JI. Low-molecular-weight heparin does not prevent recurrent placenta-mediated pregnancy complications: an individual patient data meta-analysis of randomized controlled trials Lancet 2016 Nov 26;388(10060):2629-2641.

  • Rodger MA, Hague WM, Kingdom J, et al for the TIPPS Investigators Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial Lancet 2014 Nov 8;384(9955):1673-83.

  • Rodger MA, Walker MC, Smith GN et al. Is thrombophilia associated with placenta-mediated pregnancy complications. A Prospective Cohort Study. J Thromb Haemost 2014;12:469-478.

  • Rodger MA, Kahn SR, Wells PS et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008;179:417-426.